U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07415044) titled 'LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis' on Feb. 06.
Brief Summary: The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally.
The study will last up to approximately 108 weeks, excluding screening.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Ulcerative Colitis (UC)
Ulcerative Colitis, Active Moderate
Ulcerative Colitis, Active Severe
Intervention:
DRUG: LY4268989
Administered orally
DRUG: ...